Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.65 |
| ▸ | NOS1 | P29475 | 4/20 | 0.65 |
| ▸ | NOS3 | P29474 | 1/20 | 0.65 |
| ▸ | NOS2 | P35228 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL23878450 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL22444385 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL22444393 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL23878380 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL28158653 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL23878381 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| SCHEMBL448067 | 0.98 | IDO1 (0.63) | IDO1NOS1NOS3NOS2CA12 | |
| Cyclopentane SCHEMBL11297129 | 0.94 | IDO1 (0.59) | IDO1NOS1NOS3NOS2CA12 | |
| Methyl Alcohol SCHEMBL28258509 | 0.94 | IDO1 (0.59) | IDO1NOS1NOS3NOS2CA12 | |
| Butane SCHEMBL3696734 | 0.92 | IDO1 (0.57) | IDO1NOS1NOS3NOS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-02-03 | — | — | US | claimed |
| EP-4514595-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-4240578-B1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC (CH) | 2024-12-18 | — | — | EP | claimed |
| CN-117736707-A | 230 ℃ resistant high-salt resistant high-density water-based drilling fluid and preparation method and application thereof | 中国石油大学(华东) | 2024-03-22 | — | — | CN | claimed |
| US-11886045-B2 | Method for making photochromic contact lenses | ALCON INC. (CH) | 2024-01-30 | — | — | US | claimed |
| WO-2023209570-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | WO | claimed |
| US-20230339149-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-10-26 | — | — | US | claimed |
| EP-4240578-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | Alcon Inc. (CH) | 2023-09-13 | — | — | EP | claimed |
| CN-115160513-B | 240 ℃ high-temperature resistant high-salt resistant rigid-flexible blocking agent and preparation method thereof | 中国石油大学(华东) | 2023-08-01 | — | — | CN | claimed |
| CN-114605653-A | Preparation method and application of biological thermoplastic elastomer replacing SBS | 东南大学 | 2022-06-10 | — | — | CN | claimed |
| US-20090012199-A1 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfolidated silicate nanocomposite | NATIONAL SCIENCE FOUNDATION | 2009-01-08 | — | — | US | claimed |
| WO-2008000766-A2 | POLYMERISATION FROM A DIALLYLAMINE AND A COMPOUND CONTAINING A MACROMOLECULAR CHAIN CONSISTING OF UNITS DERIVED FROM SUCH AN AMINE | RHODIA OPERATIONS (FR) | 2008-01-03 | — | — | WO | claimed |
| JP-2007517119-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20070145625-A1 | Process for crosslinking free-radical crosslinkable polymers | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-06-28 | — | — | US | claimed |
| CN-1918236-A | Free radical crosslinkable polymer: improved crosslinking process and composition | DOW GLOBAL TECHNOLOGIES INC (US) | 2007-02-21 | — | — | CN | claimed |
| EP-1699881-A2 | FREE-RADICAL CROSSLINKABLE POLYMERS: IMPROVED PROCESS FOR CROSSLINKING AND COMPOSITIONS | The Dow Global Technologies Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2006055372-A2 | PHOTOINITIATOR ANCHORED TO SILICATE AND USE THEREOF TO PREPARE POLYMER EXFOLIATED SILICATE NANOCOMPOSITE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2005066280-A2 | FREE-RADICAL CROSSLINKABLE POLYMERS: IMPROVED PROCESS FOR CROSSLINKING AND COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-6265499-B1 | POLYMERIZING MIXTURE | MENICON CO., LTD. (JP) | 2001-07-24 | — | — | US | claimed |
| US-3962304-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | INF2, CRYZ, CRYAA | IDO1 1074/4885NOS1 735/4885NOS3 743/4885 |
| US-20090012199-A1 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfolidated silicate nanocomposite | MSN, NAPA, SELE | IDO1 3646/4885NOS1 1887/4885NOS3 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.